Strengthening Global Partnerships in Hemoglobin Diagnostics
During the Belgian economic mission led by Princess Astrid of Belgium, SYnAbs reinforced its role as a specialized provider of monoclonal antibodies for detecting hemoglobin variants.
The mission provided a unique platform to engage with key stakeholders in India’s diagnostic ecosystem, particularly in the field of:
- Sickle cell disease screening (HbS detection)
- Hemoglobin variant identification (HbA, HbC, HbE)
- β-thalassemia diagnostics (HbA2, HbF)
- Total hemoglobin detection (panHb)
India represents a strategic market where clinical need, industrial capacity, and public health programs converge at scale.
A Strategic Industrial Collaboration with Tulip Diagnostics
A key milestone of the mission was the signing of a collaboration agreement with Tulip Diagnostics, a major Indian diagnostic manufacturer and a subsidiary of Revvity (formerly PerkinElmer).
This partnership focuses on the integration of SYnAbs’ monoclonal antibodies into rapid diagnostic tests (lateral flow assays).
Scope of collaboration;
-
Supply of highly specific monoclonal antibodies:
- Anti-HbA
- Anti-HbC
- Anti-HbE
- Anti-HbF
- Anti-HbA2
- Pan-hemoglobin (panHb)
- Optimization for rapid diagnostic platforms
- Industrial manufacturing and international deployment
👉 This model enables SYnAbs to focus on high-value antibody development, while leveraging Tulip Diagnostics’ industrial capabilities for large-scale production.
Quote from Julien Isoard, Chairman & CEO of SYnAbs:
"We are thrilled to partner with Tulip Diagnostics (P) Ltd, a company recognized globally for its
expertise in developing diagnostic kits and its presence in nearly 90 countries. This collaboration represents a significant advancement in the fight against hemoglobin mutation-related diseases.
We are confident that our high-quality monoclonal antibodies, combined with Tulip's proven ability to swiftly produce and distribute in-vitro diagnostic kits on a global scale, will have a
meaningful impact on patient care."
Quote from D.G. Tripathi, Group President of Tulip Diagnostics (P) Ltd, a Revvity company
"This partnership with SYnAbs is a key milestone for Tulip Diagnostics (P) Ltd. By using cutting-edge monoclonal antibodies provided by SYnAbs, we will be able
to offer more reliable and accessible diagnostic tests, which is crucial for regions where these diseases are most prevalent. This new range will complement the existing product lines while
enabling Tulip to make a significant societal impact within the Indian population"
Presenting Diagnostic Innovation to Industry Leaders
SYnAbs also presented its technologies during dedicated sessions with Indian industry leaders and healthcare stakeholders.
The presentation highlighted:
- The specificity of SYnAbs antibodies for closely related hemoglobin variants
- their compatibility with rapid diagnostic formats
- their role in enabling reliable discrimination between carriers and affected patients
These exchanges confirmed the strong alignment between SYnAbs’ expertise and the needs of large-scale screening programs.
Engagement with Global Health Stakeholders
The mission also enabled discussions with key global health actors, including representatives of the Bill & Melinda Gates Foundation.
Topics included:
- expanding access to hemoglobin diagnostics in low-resource settings
- scaling up screening programs for sickle cell disease
- improving early detection of thalassemia
Institutional Recognition at the Highest Level
SYnAbs’ participation was highlighted during official mission events, including interactions with high-level representatives and institutional stakeholders.
This visibility reinforces SYnAbs’ position as a trusted European partner in diagnostic innovation.
Real-World Impact at Scale
SYnAbs’ monoclonal antibodies are already deployed in real-world diagnostic applications.
To date, SYnAbs antibodies have contributed to the production of tens of millions of rapid diagnostic tests for hemoglobinopathies, including an estimated 30–35 million tests in India.
These tests are used in screening programs targeting:
- sickle cell disease
- hemoglobin variants
- thalassemia-related disorders
A Clear Strategic Positioning
SYnAbs’ approach is deliberately focused:
👉 to serve as a key supplier of high-performance monoclonal antibodies for diagnostic applications worldwide
Rather than competing in manufacturing, SYnAbs integrates into global value chains by providing:
- critical biological components
- high specificity reagents
- solutions compatible with industrial diagnostic platforms
Conclusion
The Belgian economic mission to India marked a significant step forward for SYnAbs.
Beyond institutional engagement, it delivered:
- a strategic industrial partnership
- strong alignment with global health initiatives
- tangible impact in large-scale diagnostic deployment
👉 SYnAbs continues to expand its role as a key enabler in hemoglobin variant detection, supporting the global fight against sickle cell disease and thalassemia.
